- Home
- TCMD vs AUTL Comparison
TCMD vs AUTL Comparison
Compare TCMD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCMD
- AUTL
- Stock Information
- Founded
- TCMD 1995
- AUTL 2014
- Country
- TCMD United States
- AUTL United Kingdom
- Employees
- TCMD N/A
- AUTL N/A
- Industry
- TCMD Medical/Dental Instruments
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCMD Health Care
- AUTL Health Care
- Exchange
- TCMD Nasdaq
- AUTL Nasdaq
- Market Cap
- TCMD 314.0M
- AUTL 359.3M
- IPO Year
- TCMD 2016
- AUTL 2018
- Fundamental
- Price
- TCMD $9.54
- AUTL $1.32
- Analyst Decision
- TCMD Hold
- AUTL Strong Buy
- Analyst Count
- TCMD 3
- AUTL 5
- Target Price
- TCMD $16.00
- AUTL $9.32
- AVG Volume (30 Days)
- TCMD 317.5K
- AUTL 2.4M
- Earning Date
- TCMD 05-05-2025
- AUTL 05-08-2025
- Dividend Yield
- TCMD N/A
- AUTL N/A
- EPS Growth
- TCMD N/A
- AUTL N/A
- EPS
- TCMD 0.66
- AUTL N/A
- Revenue
- TCMD $293,164,000.00
- AUTL $9,011,000.00
- Revenue This Year
- TCMD $10.68
- AUTL $277.74
- Revenue Next Year
- TCMD $8.82
- AUTL $221.89
- P/E Ratio
- TCMD $14.45
- AUTL N/A
- Revenue Growth
- TCMD 5.96
- AUTL N/A
- 52 Week Low
- TCMD $8.61
- AUTL $1.11
- 52 Week High
- TCMD $21.10
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- TCMD 20.45
- AUTL 45.63
- Support Level
- TCMD $8.61
- AUTL $1.15
- Resistance Level
- TCMD $14.22
- AUTL $1.44
- Average True Range (ATR)
- TCMD 0.48
- AUTL 0.14
- MACD
- TCMD -0.51
- AUTL 0.01
- Stochastic Oscillator
- TCMD 15.50
- AUTL 29.82
About TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.